pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Aug 10·1 min read
save

Global Ebola preparedness fixated on one strain, leaving gaps for other species

Aug 10, 2026·read at STAT ↗Negative

Krutika Kuppalli, a former WHO medical officer, and virologist Placide Mbala write that the world’s readiness for Ebola has been narrowly focused. They draw on Kuppalli’s experience in the 2014‑2016 West Africa outbreak and Mbala’s work in the Democratic Republic of the Congo.

The authors explain that Ebola virus disease is caused by several distinct virus species, each with different diagnostic and therapeutic needs. Yet for most of the past decade, global efforts have centered on Zaire ebolavirus, the strain behind the West Africa crisis.

The ongoing Bundibugyo virus outbreak in the DRC has become the country’s largest Ebola event and the second‑largest epidemic ever recorded. Its rapid spread underscores the danger of overlooking non‑Zaire strains.

Kuppalli and Mbala argue that this situation exposes a fundamental blind spot in global health preparedness, urging a broader focus that includes all Ebola species.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: We prepared for Ebola — but not this Ebola”

read at STAT ↗
1,514 words · retrieved Aug 10
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Moderna, Inc.
drugs
Ebola Zaire vaccine5NVCov-2R2VEKLURY2remdesivir2
topics
Vaccine10Diagnostics Company6Vaccines6Infectious Disease2Monoclonal Antibody2ImmunologySmall MoleculemRNA TherapeuticmRNA Vaccine

related stories

  • Aug 10Opinion: We prepared for Ebola — but not this EbolaSTAT
  • 1d agoNovo workforce down 13,000BioSpace
  • Jul 17Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advancesBioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: Sling reels in $123M; Circle gathers $92.5MFierce Biotech
  • Sep 145 drugmakers chasing Merck and Moderna in the cancer vaccine raceBioSpace